吸入依前列醇与俯卧位通气对插管COVID-19难治性低氧血症患者的疗效
该回顾性研究纳入43例接受有创通气的成人COVID-19难治性低氧血症患者,评估吸入依前列醇与俯卧位通气单独及联合应用的效果。结果显示,单独俯卧位或单独吸入依前列醇前后PaO2/FiO2无显著差异,但联合应用后PaO2/FiO2从84.0 mmHg升至124.7 mmHg(p<0.001),同时启动的14例患者从78.9升至150.2 mmHg(p=0.005)。27例(63%)联合治疗氧合改善>20%,应答者死亡率显著低于无应答者(52% vs 81%,p=0.025)。结论需随机前瞻性试验验证。
要点
- 联合吸入依前列醇与俯卧位通气后PaO2/FiO2从84.0 mmHg升至124.7 mmHg(p<0.001),单独使用任一措施无显著改善。
- 同时启动吸入依前列醇和俯卧位的14例患者PaO2/FiO2从78.9 mmHg升至150.2 mmHg(p=0.005)。
- 27例(63%)联合治疗氧合改善>20%,应答者死亡率52%显著低于无应答者81%(p=0.025)。
- 纳入标准为有创通气期间接受吸入依前列醇和俯卧位通气的成人COVID-19患者;PaO2/FiO2>150 mmHg者排除。
- 该研究为回顾性设计,样本量43例,结论需随机前瞻性临床试验验证。
适用人群与场景
- 成人COVID-19有创机械通气患者,接受吸入依前列醇和俯卧位通气。
- 排除:吸入依前列醇在外院启动、俯卧位终止后启动、ECMO或心肺复苏期间启动、PaO2/FiO2>150 mmHg者。
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 对COVID-19有创通气难治性低氧血症患者,可考虑联合吸入依前列醇与俯卧位通气;原文未提供依前列醇剂量、给药频次或疗程。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 回顾性研究,43例成人COVID-19有创通气患者,单中心学术医院成人ICU。
- 单独俯卧位或单独吸入依前列醇前后PaO2/FiO2无显著差异(89.1 vs 97.6 mmHg,p=0.393)。
- 联合吸入依前列醇与俯卧位后PaO2/FiO2从84.0升至124.7 mmHg(p<0.001)。
- 同时启动联合治疗的14例患者PaO2/FiO2从78.9升至150.2 mmHg(p=0.005)。
- 27例(63%)联合治疗氧合改善>20%;应答者死亡率52% vs 无应答者81%(p=0.025)。
证据类型、等级与局限
- 回顾性研究,单中心,样本量43例,开放标签设计,需随机前瞻性试验验证。
对床旁实践的改变
- 在COVID-19有创通气难治性低氧血症患者中,联合吸入依前列醇与俯卧位通气可能改善氧合,应答者死亡率更低;但证据来自回顾性单中心研究,不能作为常规推荐,需前瞻性验证。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: To evaluate the effects of inhaled epoprostenol and prone positioning, individually and in combination in mechanically ventilated patients with coronavirus disease 2019 and refractory hypoxemia.
DESIGN: Retrospective study.
SETTING: Academic hospital adult ICUs.
PATIENTS: Adult patients who received inhaled epoprostenol and prone positioning during invasive ventilation were enrolled. Patients were excluded if inhaled epoprostenol was initiated: 1) at an outside hospital, 2) after prone positioning was terminated, 3) during extracorporeal membrane oxygenation or cardiopulmonary resuscitation, and 4) with Pao2/Fio2 greater than 150 mm Hg.
INTERVENTIONS: Inhaled epoprostenol and prone positioning.
RESULTS: Of the 43 eligible patients, 22 and seven received prone positioning and inhaled epoprostenol alone, respectively, prior to their use in combination, Pao2/Fio2 was not different pre- and post-prone positioning or inhaled epoprostenol individually (89.1 [30.6] vs 97.6 [30.2] mm Hg; p = 0.393) but improved after the combined use of inhaled epoprostenol and prone positioning (84.0 [25.6] vs 124.7 [62.7] mm Hg; p < 0.001). While inhaled epoprostenol and prone positioning were instituted simultaneously in 14 patients, Pao2/Fio2 was significantly improved (78.9 [27.0] vs 150.2 [56.2] mm Hg, p = 0.005) with the combination. Twenty-seven patients (63%) had greater than 20% improvement in oxygenation with the combination of inhaled epoprostenol and prone positioning, and responders had lower mortality than nonresponders (52 vs 81%; p = 0.025).
CONCLUSIONS: In critically ill, mechanically ventilated patients with coronavirus disease 2019 who had refractory hypoxemia, oxygenation improved to a greater extent with combined use of inhaled epoprostenol and prone positioning than with each treatment individually. A higher proportion of responders to combined inhaled epoprostenol and prone positioning survived compared with nonresponders. These findings need to be validated by randomized, prospective clinical trials.
参考来源
- Li J, Fink JB, Augustynovich AE, et al. Effects of Inhaled Epoprostenol and Prone Positioning in Intubated Coronavirus Disease 2019 Patients With Refractory Hypoxemia. Crit Care Explor. 2020. PMID: 33354678. doi:10.1097/CCE.0000000000000307
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。